Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: RTOG 0924 - Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

 


RTOG 0924 - Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial


Trial Focus

Prostate Cancer

Objective

         This is a clinical trial of radiation treatments that will be administered by Radiation Therapy which is standard of care and hormone thereapy that will be administered by mouth and is standard of care.

IRB Protocol #

12-1359

Trial Status

OPEN

Principle Investigator

BRIAN KAVANAGH

Sponsor

RTOG

Contact

MONICA ROBISCHON at (720) 848-0661 or MONICA.ROBISCHON@UCDENVER.EDU

Location

Dept Of Veterans Affairs Medical Center University of Colorado Hospital Dept Of Veterans Affairs Medical Center University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period that can last up to 2 months with radiation therapy or 6 weeks with radiation therapy and brachytherapy. Hormone therapy will last 6-32 months, determined by the doctor. A follow up period will consist of follow-up exams every 3 months for the first year, every 6 months for years 2-5, and yearly after 5 years. // Eligibility criteria include but are not limited to males 18 years or older with favorable intermediate or favorable high risk prostate cancer.Eligibility criteria include but are not limited to males 18 years or older with favorable intermediate or favorable high risk prostate cancer.